OTLK.NASDAQOutlook Therapeutics, INC
10-Q: Outlook Therapeutics Reports Net Income for Q1 2025 Amidst Ongoing Efforts to Secure Funding and Regulatory Approval for LYTENAVA
Sentiment:
Quarterly Report
Outlook Therapeutics reports a net income of $17.4 million for the quarter ended December 31, 2024, while navigating financial uncertainties and pursuing regulatory approval for its lead product candidate, LYTENAVA.
Capital raiseThe company entered into a Securities Purchase Agreement with Avondale Capital for a $33.1 million unsecured convertible promissory note.The company completed a warrant inducement transaction generating $15.7 million in net proceeds.The company may issue and sell shares of its common stock having an aggregate offering price of up to $100.0 million from time to time through BTIG.
Worse than expectedThe NORSE EIGHT trial did not meet its pre-specified non-inferiority endpoint at week 8, indicating worse than expected results.The company has a working capital deficit and an accumulated deficit, and there is substantial doubt about its ability to continue as a going concern, indicating worse than expected financial stability.
Summary
- Outlook Therapeutics reported a net income of $17.4 million for the three months ended December 31, 2024, compared to a net loss of $11.2 million for the same period in 2023.
- The company is focused on obtaining regulatory approval for ONS-5010/LYTENAVA and preparing for its potential launch in the EU, UK, and the United States.
- ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint in the NORSE EIGHT clinical trial, but data showed improvement in vision and biologic activity.
- The company plans to resubmit the BLA for ONS-5010/LYTENAVA in the first quarter of calendar 2025.
- Outlook Therapeutics is addressing CMC issues raised by the FDA in the Complete Response Letter (CRL).
- The company is actively seeking additional financing to fund operations and the commercial development of ONS-5010/LYTENAVA.
- As of December 31, 2024, the company had a working capital deficit and an accumulated deficit of $525,907,286.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company entered into a Securities Purchase Agreement with Avondale Capital for a $33.1 million unsecured convertible promissory note.
- The company completed a warrant inducement transaction generating $15.7 million in net proceeds.
- General and administrative expenses increased by $6.2 million compared to the same period in the previous year, due to prelaunch expenses for Europe and increased compensation costs.
- Research and development expenses increased by $5.1 million compared to the same period in the previous year, primarily due to the NORSE EIGHT clinical trial.
- The company is involved in a securities class action lawsuit and a shareholder derivative action related to alleged misstatements regarding the BLA for ONS-5010/LYTENAVA.
Sentiment
Score: 5
Explanation: The document presents a mixed sentiment. While the company reported a net income for the quarter, it also faces significant financial challenges and regulatory hurdles. The failure of the NORSE EIGHT trial to meet its primary endpoint is a negative factor, but the company is taking steps to address the issues and resubmit the BLA. The company's ability to secure additional financing and successfully commercialize its product candidates will be critical to its future success.
Positives
- The company reported a net income of $17.4 million for the three months ended December 31, 2024, compared to a net loss of $11.2 million for the same period in 2023.
- The company received marketing authorization for LYTENAVA in the EU and UK for the treatment of wet AMD.
- The NORSE EIGHT trial, while not meeting its primary endpoint, demonstrated improvement in vision and biologic activity with a favorable safety profile.
- The company completed a warrant inducement transaction generating $15.7 million in net proceeds.
- The company entered into a Securities Purchase Agreement with Avondale Capital for a $33.1 million unsecured convertible promissory note.
Negatives
- The NORSE EIGHT trial did not meet its pre-specified non-inferiority endpoint at week 8.
- The company has a working capital deficit and an accumulated deficit of $525,907,286 as of December 31, 2024.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company is involved in a securities class action lawsuit and a shareholder derivative action.
- The company's future operations are highly dependent on securing additional financing, successfully marketing its product candidates, and obtaining regulatory approval.
Risks
- The company's ability to obtain regulatory approval for ONS-5010/LYTENAVA is uncertain.
- The company's future operations are highly dependent on securing additional financing, which may not be available on favorable terms or at all.
- The company faces competition from other biotechnology and pharmaceutical companies.
- The company is subject to the risks associated with clinical trials, including delays, unexpected results, and the need for additional trials.
- The company is involved in a securities class action lawsuit and a shareholder derivative action, which could result in significant costs and liabilities.
- The company's ability to successfully commercialize ONS-5010/LYTENAVA is dependent on market acceptance and reimbursement from government and third-party payors.
- The company's reliance on contract manufacturing organizations and other vendors poses risks to its supply chain and manufacturing capabilities.
- The company's intellectual property rights may be challenged or infringed upon by third parties.
- The company's ability to maintain its Nasdaq listing is critical for accessing capital markets.
Future Outlook
The company plans to resubmit the BLA for ONS-5010/LYTENAVA in the first quarter of calendar 2025 and is preparing for a potential launch of LYTENAVA in the EU, UK, and the United States. The company's future operations are highly dependent on securing additional financing, successfully marketing its product candidates, and obtaining regulatory approval.
Management Comments
- Management is currently evaluating different strategies to obtain the required funding for future operations.
- Management does not believe that the existing cash and cash equivalents as of December 31, 2024, together with net proceeds from the sale of shares of common stock in the Warrant Inducement Transaction, are sufficient to fund the Company's operations through one year from the date of this Quarterly Report on Form 10-Q.
Industry Context
The company is developing ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. If approved, ONS-5010/LYTENAVA has the potential to mitigate risks associated with off-label use of unapproved bevacizumab, which is commonly used by retina physicians in the United States.
Comparison to Industry Standards
- The document does not provide enough information to make a detailed comparison to industry standards.
- However, the document does mention that 66.3% of retina physicians in the United States state off-label repackaged bevacizumab is their most commonly used first-line anti-VEGF, which suggests that there is a significant market opportunity for an approved bevacizumab product for retinal diseases.
- Competitors in the wet AMD market include companies that market ranibizumab (LUCENTIS).
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Not specified | Lawrence A. Kenyon (Interim) | December 2024 | Resignation of the former Chief Executive Officer |
Legal Proceedings
- A securities class action lawsuit was filed against the company and certain of its officers in the United States District Court for the District of New Jersey.
- Certain of the company's officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware.
Related Party Transactions
- GMS, the Company's largest stockholder affiliated with Yezan Haddadin and Faisal G. Sukhtian, directors of the Company participated in the Warrant Inducement Transaction.
- Syntone Ventures, LLC, or Syntone, pursuant to which Syntone agreed to exercise existing warrants, or the Existing Syntone Warrants, for an aggregate of 1,071,429 shares of common stock at a reduced exercise price of $2.51 per share.
Stakeholder Impact
- Shareholders face potential dilution from future equity offerings and the conversion of convertible debt.
- Employees were affected by a workforce reduction in December 2024.
- Customers (patients) may benefit from the potential approval and commercialization of ONS-5010/LYTENAVA.
- Suppliers and creditors face risks associated with the company's financial uncertainties and ability to continue as a going concern.
Next Steps
- Resubmit the BLA for ONS-5010/LYTENAVA in the first quarter of calendar 2025.
- Prepare for the potential launch of LYTENAVA in the EU, UK, and the United States.
- Seek additional financing to fund operations and the commercial development of ONS-5010/LYTENAVA.
- Obtain stockholder approval for the issuance of shares exceeding 19.99% of the outstanding common stock upon conversion of the January 2025 Note.
Key Dates
| Date | Description |
|---|---|
| January 5, 2010 | Outlook Therapeutics, Inc. was incorporated in New Jersey. |
| October 2015 | Reincorporated in Delaware. |
| December 22, 2017 | Date of Note and Warrant Purchase Agreement. |
| April 2018 | End of Phase 2 meeting with the FDA. |
| November 2018 | Changed its name to Outlook Therapeutics, Inc. |
| Q1 2019 | Filed investigational new drug application, or IND, with the FDA. |
| May 22, 2020 | Entered into a stock purchase agreement with Syntone. |
| June 2020 | Sold and issued shares of common stock to Syntone. |
| April 2021 | Formation of Syntone JV. |
| March 2021 | Reported results from NORSE THREE. |
| March 2021 | Entered into a three-year term corporate office lease for its former corporate headquarters in Iselin, New Jersey. |
| August 3, 2021 August 29, 2023 | Period of alleged false and misleading statements related to the BLA. |
| August 2021 | Reported topline results from NORSE TWO. |
| November 2021 | Began enrolling patients in NORSE SEVEN clinical trial. |
| March 2022 | Submitted a BLA with the FDA for ONS-5010/LYTENAVA. |
| May 2022 | Voluntarily withdrew BLA to provide additional information requested by the FDA. |
| August 30, 2022 | Re-submitted the BLA to the FDA for ONS-5010/LYTENAVA. |
| October 2022 | Received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023. |
| October 2022 | Submitted a Marketing Authorization Application, or MAA, for ONS-5010/LYTENAVA with the European Medicines Agency, or EMA. |
| December 22, 2022 | Entered into a Securities Purchase Agreement and issued the December 2022 Note. |
| December 28, 2022 | Received net proceeds of $18,052,461 upon the closing. |
| August 29, 2023 | Received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle. |
| May 16, 2023 | Entered into an At-the-Market Sales Agreement with BTIG, LLC. |
| November 3, 2023 | A securities class action lawsuit was filed against the Company and certain of its officers. |
| December 2023 | Extended the maturity of the December 2022 Note from January 1, 2024 to April 1, 2024. |
| December 2023 | Submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT). |
| January 22, 2024 | Entered into an amendment to the December 2022 Note. |
| January 2024 | Received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA. |
| March 7, 2024 | The number of authorized shares of common stock under the Company's Certificate of Incorporation was increased from 21,250,000 shares to 60,000,000 shares. |
| March 14, 2024 | Implemented a one-for-twenty reverse stock split of its common stock. |
| March 18, 2024 | Closing of the private placement. |
| March 22, 2024 | The EMAs Committee for Medicinal Products for Human Use, or CHMP issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA (bevacizumab gamma). |
| March 2024 | Entered into a five-year term corporate office lease for its new corporate headquarters in Iselin, New Jersey. |
| April 1, 2024 | The Note Amendment became effective. |
| April 2024 | Submitted a MAA to the MHRA in the UK seeking approval of ONS-5010/LYTENAVA (bevacizumab gamma). |
| April 30, 2024 | Corporate office lease for its former corporate headquarters in Iselin, New Jersey ended. |
| May 1, 2024 | Corporate office lease for its new corporate headquarters in Iselin, New Jersey commenced. |
| May 13, 2024 | Filed a Certificate of Elimination to its Certificate of Incorporation. |
| May 27, 2024 | Received a marketing authorization from the European Commission for ONS-5010/LYTENAVA for the treatment of wet AMD. |
| June 25, 2024 | The defendants filed a motion to dismiss the amended class action complaint in its entirety. |
| July 8, 2024 | Received marketing authorization for ONS-5010/LYTENAVA for the treatment of wet AMD in the UK. |
| August 2024 | The Company's stockholders approved the amendment and restatement of the 2015 Plan and, in connection with amending and restating the 2015 Plan, the name of the 2015 Plan was updated to the Outlook Therapeutics, Inc. 2024 Equity Incentive Plan. |
| December 4, 2024 | Received a recommendation by the UK National Institute for Health and Care Excellence, or NICE, for LYTENAVA (bevacizumab gamma), as an option for the treatment of wet AMD. |
| October 10, 2024 | Certain of the company's officers and directors were named as defendants in a shareholder derivative action filed in the District Court of the District of Delaware. |
| November 2024 | Reported that ONS-5010/LYTENAVA did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the SPA. |
| January 16, 2025 | Entered into warrant exercise inducement offer letter agreements with GMS Ventures and Investments and certain other holders of existing warrants. |
| January 2025 | Reported the complete data and safety results from NORSE EIGHT. |
| January 31, 2025 | Entered into a Securities Purchase Agreement (SPA) with Avondale Capital, LLC. |
| February 6, 2025 | The court entered an order granting the motion to dismiss and dismissing the complaint without prejudice and with leave to amend. |
| February 12, 2025 | The number of shares of the registrants common stock, $0.01 par value per share, outstanding was 32,017,179. |
| Q2 2025 | Plans to launch directly in the initial markets of Germany and the UK. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.